泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

午间休市 11-19 12:30:01

33.700

+0.250

+0.75%

最高34.500	最低33.400	成交量58.46万
今开33.900	昨收33.450	日振幅3.29%
总市值291.49亿	流通市值41.45亿	总股本8.65亿
成交额1,986万	换手率0.48%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":33.7,"timestamp":1731990601231,"preClose":33.45,"halted":0,"volume":584600,"delay":0,"floatShares":123000000,"shares":864948570,"eps":2.5186844,"marketStatus":"午间休市","marketStatusCode":3,"change":0.25,"latestTime":"11-19 12:30:01","open":33.9,"high":34.5,"low":33.4,"amount":19860585,"amplitude":0.032885,"askPrice":33.7,"askSize":300,"bidPrice":33.65,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":1.1922545999968877,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731992400000},"adr":0,"listingDate":1596729600000,"adjPreClose":33.45,"dividendRate":0.018143,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.595062,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":60.63,"timestamp":1731990864000,"preClose":60.05,"halted":0,"volume":4673556,"delay":0,"premium":"-48.34"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2484954891","title":"【港股通】康希诺生物(06185)涨超6% Hib疫苗近日正式启动I期临床试验 并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2484954891","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484954891?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:10","pubTimestamp":1731985843,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康希诺生物 早盘股价震荡走高，截至发稿，报30港元，涨6.19%，成交额4261.15万港元。消息面上，公司发布公告，公司冻干b型流感嗜血杆菌结合疫苗于近日正式启动I期临床试验，并完成首例受试者入组。Hib疫苗为公司正在研发的以组分百白破为基础的联合疫苗的组成部分。I期临床试验为评价在2月龄及以上人群中接种该疫苗安全性和免疫原性的随机、部分盲法、阳性对照的临床试验。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","159646","06185","BK1583","BK1515","BK1576","BK1574","HSTECH","BK1141","YANG","BK1191","BK1161","03347"],"gpt_icon":1},{"id":"2484951727","title":"科伦博泰生物-B现涨逾3% SKB535新药临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484951727","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484951727?lang=zh_cn&edition=full","pubTime":"2024-11-19 11:04","pubTimestamp":1731985440,"startTime":"0","endTime":"0","summary":"　　科伦博泰生物-B早盘上涨2.73%，现报158.20港元，成交额1444.31万港元。　　科伦博泰生物-B发布公告，公司已于2024年11月15日收到国家药品监督管理局药品审评中心批准公司开发的创新药物SKB535新药临床试验申请的临床试验通知书。根据NMPA官网公布，SKB535为NMPA批准的首个优化创新药临床试验审评审批试点项目，审评审批用时21日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-19/doc-incwqkxq9416937.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-19/doc-incwqkxq9416937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06990","BK1576","03347","LU0196878994.USD","BK1141","BK1161","BK1583"],"gpt_icon":0},{"id":"2484599199","title":"港股异动 | 科伦博泰生物-B(06990)涨超3% SKB535、SKB571新药临床试验申请均获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484599199","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484599199?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:49","pubTimestamp":1731984571,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超3%，截至发稿，涨2.86%，报158.4港元，成交额1327.31万港元。根据NMPA官网公布，SKB535为NMPA批准的首个优化创新药临床试验审评审批试点项目，审评审批用时21日。同日，科伦博泰生物-B发布公告，公司已于2024年11月15日收到国家药品监督管理局药品审评中心批准公司开发的新型药物SKB571新药临床试验申请的临床试验通知书。于2024年第三季度，公司获默沙东告知其关于SKB571行使独家选择权的事宜。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0196878994.USD","BK1141","03347","06990","BK1576","BK1583"],"gpt_icon":0},{"id":"2484955135","title":"康希诺生物现涨超5% 预防急性下呼吸道感染疫苗启动I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955135","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484955135?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:12","pubTimestamp":1731982349,"startTime":"0","endTime":"0","summary":"康希诺生物（06185）早盘上涨5.49%，现报29.80港元，成交额3086.68万港元。\n　　康希诺生物公布，旗下“冻干b型流感嗜血杆菌结合疫苗”（Hib疫苗）于近日正式启动I期临床试验，并完成首例受试者入组。据介绍，流感嗜血杆菌为革兰阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之一。至于上述疫苗预期可在接种后，诱导针对Hib的体液免疫，对接种者提供保护作用。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-19/doc-incwqers9534045.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-19/doc-incwqers9534045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1515","BK1583","03347","BK1576","06185","BK1191","BK1141","BK1574","BK1161"],"gpt_icon":0},{"id":"2484553789","title":"港股异动 | 康希诺生物(06185)早盘涨超6% 预防急性下呼吸道感染疫苗启动I期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2484553789","media":"智通财经","labels":["Product Release","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484553789?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:04","pubTimestamp":1731981886,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物早盘涨超6%，截至发稿，涨5.66%，报29.7港元，成交额2403.16万港元。消息面上，康希诺生物公布，旗下“冻干b型流感嗜血杆菌结合疫苗”于近日正式启动I期临床试验，并完成首例受试者入组。据介绍，流感嗜血杆菌为革兰阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之一。此外，康希诺生物近期发布业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1515","BK1583","159646","BK1574","06185","03347","BK1191","BK1576","BK1161"],"gpt_icon":0},{"id":"2484958316","title":"南向资金11月18日净卖出泰格医药25.02万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2484958316","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484958316?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:30","pubTimestamp":1731979816,"startTime":"0","endTime":"0","summary":"11月18日，南向资金减持泰格医药25.02万股连续5日减持。截止当日收盘，港股通共持有泰格医药5783.19万股，占流通股46.96%。港股通减持金额前五个股分别为协鑫科技、新秀丽、中兴通讯、中国财险、中国海外发展。泰格医药近5个交易日下跌11.39%，港股通累计减持147.81万股；近20个交易日下跌9.96%，港股通累计减持16.09万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093254a2444fe4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093254a2444fe4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2484624405","title":"11月18日晚间公告 | 万泰生物九价HPV疫苗男性临床试验获批；多利科技获12-14亿元头部新能源车企定点","url":"https://stock-news.laohu8.com/highlight/detail?id=2484624405","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484624405?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:57","pubTimestamp":1731934649,"startTime":"0","endTime":"0","summary":"民生银行：新希望化工及其一致行动人拟举牌本行。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/baf8aa47-7b6b-4bf6-a25e-bc9d4b26692a.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/baf8aa47-7b6b-4bf6-a25e-bc9d4b26692a.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3734442","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3734442","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK1589","09633","BK1576","BK1200","BK1141","LU1981816686.USD","BK1583","03347"],"gpt_icon":0},{"id":"2484629533","title":"A股公告精选 | 10连板大千生态(603955.SH)提示风险 万泰生物(603392.SH)九价HPV疫苗男性临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484629533","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484629533?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:07","pubTimestamp":1731931669,"startTime":"0","endTime":"0","summary":"10连板大千生态(603955.SH)：公司股价可能存在短期涨幅较大后下跌的风险。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20241118/20241118200819_84415.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241118/20241118200819_84415.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["399300","603955","BK0239","09633","BK1583","BK0145","BK0201","159982","BK1576","BK1589","159646","LU1981816686.USD","03347","BK1200","BK1141","BK0178","BK0277","603392"],"gpt_icon":0},{"id":"2484402306","title":"华东医药(000963.SZ)子公司HDM1005注射液获美国FDA新药临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2484402306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484402306?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:03","pubTimestamp":1731927801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司全资子公司杭州中美华东制药有限公司(简称“中美华东”)收到美国食品药品监督管理局(简称“美国FDA”)通知，由中美华东申报的HDM1005注射液药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，GLP-1类产品具有减肥、降糖和心血管获益等作用，是相对成熟和安全的靶点。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0196","LU1969619763.USD","BK1141","BK0187","000963","BK0132","BK0188","BK1576","03347","BK1583","BK0175","LU2328871848.SGD","BK0183"],"gpt_icon":0},{"id":"2484164019","title":"华东医药(000963.SZ)子公司DR10624注射液获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2484164019","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484164019?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:01","pubTimestamp":1731927682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药 发布公告，近日，公司控股子公司浙江道尔生物科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，由道尔生物申报的DR10624注射液临床试验申请获得批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","000963","BK0183","BK1576","BK1583","BK1141","LU1969619763.USD","BK0132","BK0196","BK0209","BK0175","BK0187","LU2328871848.SGD"],"gpt_icon":0},{"id":"2484647105","title":"华东医药最新公告：HDM1005注射液获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484647105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484647105?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:40","pubTimestamp":1731926409,"startTime":"0","endTime":"0","summary":"华东医药公告，全资子公司杭州中美华东制药有限公司申报的HDM1005注射液药品临床试验申请已获得美国食品药品监督管理局批准，可在美国开展I期临床试验。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，具有降糖、减重及治疗代谢相关脂肪性肝炎的作用。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800025650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","000963","BK0187","03347","BK0175","LU2328871848.SGD","BK1576","BK1583","BK0132","LU1969619763.USD","BK0183","BK0209","BK1141"],"gpt_icon":0},{"id":"2484764717","title":"华东医药最新公告：DR10624注射液临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484764717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484764717?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:39","pubTimestamp":1731926383,"startTime":"0","endTime":"0","summary":"华东医药公告，控股子公司浙江道尔生物科技有限公司申报的DR10624注射液临床试验申请获得国家药品监督管理局批准。DR10624为一款长效三靶点激动剂，靶向FGFR1c/Klothoβ、GLP-1受体和GCG受体，适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝炎。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800025649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0132","000963","BK0183","BK0187","BK0188","BK0196","BK1583","LU2328871848.SGD","BK1576","03347","BK0209","BK1141","BK0175"],"gpt_icon":0},{"id":"2484649804","title":"万泰生物最新公告：九价HPV疫苗男性临床试验申请获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484649804","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484649804?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:29","pubTimestamp":1731922179,"startTime":"0","endTime":"0","summary":"万泰生物公告，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药监局下发的《药物临床试验通知书》，同意公司九价人乳头瘤病毒疫苗（大肠埃希菌）开展针对男性人群适应症的临床试验。该疫苗覆盖HPV16/18/31/33/45/52/58七种高危型和HPV6/11两种低危型，适用于预防由HPV6/11/16/18/31/33/45/52/58型所致的生殖器疣、阴茎/会阴/肛周癌及其癌前病变、肛门癌及其癌前病变等适应症。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800024051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1141","BK1589","09633","BK1583","LU1981816686.USD","BK1200","159646","603392","BK1576","BK0239"],"gpt_icon":0},{"id":"2484646034","title":"万泰生物(603392.SH)：九价HPV疫苗男性临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484646034","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484646034?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:28","pubTimestamp":1731922118,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局下发的《药物临床试验通知书》(通知书编号：2024LP02590)，同意公司九价人乳头瘤病毒疫苗(大肠埃希菌)(简称“九价HPV疫苗”)开展针对男性人群适应症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1583","BK1576","159646","603392","09633","BK1589","LU1981816686.USD","BK1200","BK1141","BK0239"],"gpt_icon":0},{"id":"2484064656","title":"万泰生物：九价HPV疫苗男性临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484064656","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484064656?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:27","pubTimestamp":1731922061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","BK1589","LU1981816686.USD","BK1583","BK1200","03347","603392","BK1576","159646","BK0239","09633"],"gpt_icon":0},{"id":"2484645398","title":"海思科(002653.SZ)创新药HSK44459片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645398","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484645398?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:09","pubTimestamp":1731920982,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的创新药HSK44459片境内生产药品注册临床试验申请《受理通知书》，该药品适应症：拟用于白塞病的治疗。贝赫切特病又称白塞病(Behcet’sdisease)，是一种以血管炎为基础病理改变的慢性、复发性自身免疫/炎症性疾病。主要表现为反复发作的口腔溃疡、生殖器溃疡、葡萄膜炎和皮肤损害，亦可累及周围血管、心脏、神经系统、胃肠道、关节、肺、肾等器官。HSK44459片是公司自主研发的一个全新的具有独立知识产权的治疗白塞病的药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK0188","BK1574","BK0028","BK0239","BK1583","BK1576","BK0077","002653","03347","BK0033","BK1141","06978"],"gpt_icon":0},{"id":"2484552614","title":"兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484552614","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484552614?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","300573","03347","BK1576","BK0239","BK0177","BK1141"],"gpt_icon":0},{"id":"2484614919","title":"兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614919","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614919?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于盐酸利多卡因眼用凝胶的《药物临床试验批准通知书》，盐酸利多卡因眼用凝胶适应症为适用于眼科操作中的眼表麻醉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573","BK1576","BK0239","BK0177","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2484998846","title":"科伦药业：科伦博泰两款新药临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484998846","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484998846?lang=zh_cn&edition=full","pubTime":"2024-11-18 12:00","pubTimestamp":1731902411,"startTime":"0","endTime":"0","summary":"中国财富通11月18日 - 科伦药业（002422）公告称，近日获悉，公司控股子公司科伦博泰已于11月15日收到国家药品监督管理局(NMPA)药品审评中心批准其开发的创新药物SKB535新药临床试验申请的临床试验通知书。根据NMPA官网公布，SKB535为NMPA批准的首个优化创新药临床试验审评审批试点项目，审评审批用时21日。此外，科伦博泰同日收到国家药品监督管理局药品审评中心批准其开发的新型药物SKB571新药临床试验申请的临床试验通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=zgRugQ6C2nc%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","002422","BK1576","LU1064130708.USD","LU2148510915.USD","BK1583","03347","BK1141","BK0060","BK0239"],"gpt_icon":0},{"id":"2484664436","title":"宜明昂科-B(01541)：IMM0306与来那度胺联用治疗慢性淋巴瘤的临床试验结果表明突出","url":"https://stock-news.laohu8.com/highlight/detail?id=2484664436","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484664436?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:56","pubTimestamp":1731895013,"startTime":"0","endTime":"0","summary":"IMM0306与来那度胺联用治疗慢性淋巴瘤的临床试验结果表明突出","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20241118/20241118095710_67911.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241118/20241118095710_67911.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1576","BK1161","BK1141","01541","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.1139},{"period":"1month","weight":-0.1008},{"period":"3month","weight":0.067},{"period":"6month","weight":-0.044},{"period":"1year","weight":-0.2542},{"period":"ytd","weight":-0.0359}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.100468},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009723},{"month":3,"riseRate":0.75,"avgChangeRate":0.001875},{"month":4,"riseRate":0.25,"avgChangeRate":-0.034639},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.027615},{"month":12,"riseRate":0.5,"avgChangeRate":0.06346}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}